Sequana Medical announces results of Annual General Meeting of Shareholders
25 May 2023,06:00pmCEST
Ghent, Belgium – 25 May 2023– Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "SequanaMedical"), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, today announces that all proposed resolutions submitted to the Annual General Meeting of Shareholders were approved at the meeting held today at 09:00 am CEST.
The items on the agenda of the meeting included (amongst other things) the approval of a number of resolutions relating to the financial year ended on 31 December 2022 and the application of Article 7:228 of the Belgian Companies and Associations Code.
The minutes of the shareholders' meeting can be accessed on the Company’s website.
For more information, please contact:
Director Investor Relations
T: +32 (0)498 05 35 79
Optimum Strategic Communications
Nick Bastin, Jonathan Edwards, Vici Rabbetts
T: +44 (0) 208 078 4357
About Sequana Medical
Sequana Medical NV is a pioneer in treating fluid overload, a serious and frequent clinical complication in patients with liver disease, heart failure and cancer. These patients can have up to 15 liters of extra fluid in their bodies, causing major medical issues including increased mortality, repeated hospitalizations, severe pain, difficulty breathing and restricted mobility that severely impacts daily life. Although diuretics are standard of care, the problem is that in many patients they are no longer effective and / or tolerable. There are limited effective treatment options for these patients, resulting in poor clinical outcomes, high costs and a major impact on their quality of life. Sequana Medical is seeking to provide innovative treatment options for this large and growing “diuretic-resistant” patient population.
alfapump® and DSR® are Sequana Medical's proprietary platforms that work with the body to treat diuretic-resistant fluid overload, delivering major clinical and quality of life benefits for patients and reducing costs for healthcare systems. The Company has reported positive primary endpoint data from the North American pivotal POSEIDON trial of the alfapump in recurrent or refractory ascites due to liver cirrhosis, enabling the filing of a Pre-Market Approval (PMA) application with the FDA, planned for H2 2023. Having delivered clinical proof-of-concept for DSR as a disease-modifying drug program for the treatment of heart failure, the Company will commence MOJAVE, a US randomized controlled multi-center Phase 1/2a clinical trial of DSR 2.0, with initial data expected in Q4 2023.
Sequana Medical is listed on Euronext Brussels (Ticker: SEQUA.BR) and headquartered in Ghent, Belgium. For further information, please visit www.sequanamedical.com.
Important Regulatory Disclaimers
The alfapump® system is currently not approved in the United States or Canada. In the United States and Canada, the alfapump system is currently under clinical investigation (POSEIDON Trial) and is being studied in adult patients with refractory or recurrent ascites due to cirrhosis. For more information regarding the POSEIDON clinical trial see www.poseidonstudy.com. DSR® therapy is still in development and it should be noted that any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed. There is no link between DSR therapy and ongoing investigations with the alfapump system in Europe, the United States or Canada.
Note: alfapump® and DSR® are registered trademarks.
This press release may contain predictions, estimates or other information that might be considered forward-looking statements.
Such forward-looking statements are not guarantees of future performance. These forward-looking statements represent the current judgment of Sequana Medical on what the future holds, and are subject to risks and uncertainties that could cause actual results to differ materially. Sequana Medical expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release, except if specifically required to do so by law or regulation. You should not place undue reliance on forward-looking statements, which reflect the opinions of Sequana Medical only as of the date of this press release.
AttachmentsTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Evaxion’s AI technology identifies cancer vaccine targets associated with longer progression-free survival of melanoma patients in the EVX-01 Phase 1 clinical trial3.6.2023 23:00:00 CEST | Press release
The clinical trial of the personalized cancer vaccine EVX-01 met its primary endpoints of safety and tolerabilityPositive clinical responses were reported in 8 out of 12 EVX-01 treated patientsHigh-quality neoantigens, predicted by AI technology, were associated with longer progression-free survivalStrong vaccine-specific immune responses were induced in all 12 EVX-01 treated patients Higher EVX-01 dose induced a stronger immune response and was associated with improved clinical outcome COPENHAGEN, Denmark, June 03, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-powered immunotherapies, today presented promising clinical data from its EVX-01 Phase 1 dose escalation trial in metastatic melanoma at the 2023 ASCO annual meeting in Chicago, Illinois. The Phase 1 trial successfully met primary endpoints for safety and tolerability of EVX-01 in metastatic melanoma patients
BW Offshore: Short-term contract extension for Espoir Ivoirien3.6.2023 16:39:00 CEST | Press release
Short-term contract extensionfor Espoir Ivoirien BW Offshore has signed a short-term extension for the lease and operation of the FPSO Espoir Ivoirien in order to discuss a potential purchase of the FPSO by the client. The firm period has been extended until 9 June 2023. For further information, please contact: Ståle Andreassen, CFO, +47 91 71 86 55 Anders S. Platou, Head of Corporate Finance & Strategy, +47 99 50 47 40 IR@bwoffshore.com or www.bwoffshore.com About BW Offshore: BW Offshore engineers innovative floating production solutions. The Company has a fleet of 8 FPSOs with potential and ambition to grow. By leveraging four decades of offshore operations and project execution, the Company creates tailored offshore energy solutions for evolving markets world-wide. BW Offshore has around 2,000 employees and is publicly listed on the Oslo Stock Exchange. This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act.
Jobindex A/S meddeler sin hensigt om afnotering og tilbud fra Danielsen 2 ApS til aktionærerne om køb af deres aktier til 1.900 kr. pr. aktie2.6.2023 20:16:00 CEST | pressemeddelelse
Selskabsmeddelelse nr. 6 / 2023 København, Danmark 2. juni 2023 – Jobindex A/S (“Jobindex” eller “Selskabet”), meddeler, at Jobindex i dag har besluttet at lade Selskabets aktier slette fra handel og officiel notering fra Nasdaq First North Growth Market Denmark (“Nasdaq First North”) og bemyndiget adm. direktør Kaare Danielsen til at indgive anmodning herom til Nasdaq Copenhagen A/S inden den 1. oktober 2023 samt at Danielsen 2 ApS (“Tilbudsgiver”) fremsætter et frivilligt ureguleret offentligt købstilbud på 1.900 kr. pr. aktie (det “Offentlige Købstilbud”) til alle aktionærer i Jobindex med undtagelse af Tilbudsgiver og Selskabet for så vidt angår egne aktier. For aktionærerne i Jobindex A/S betyder dette, at man har valget imellem at: Acceptere det Offentlige Købstilbud, der indebærer en præmie på ca. 8,6% ift. lukkekursen pr. 2. juni 2023 og en præmie på ca. 9,7% ift. de sidste 12 handelsdages volumenvægtede gennemsnitskurs (VWAP); ellerFortsætte uændret som aktionær i Jobindex A/S
Nokia Corporation: Repurchase of own shares on 02.06.20232.6.2023 20:00:00 CEST | Press release
Nokia Corporation Stock Exchange Release 2 June 2023 at 21:00 EEST Nokia Corporation: Repurchase of own shares on 02.06.2023 Espoo, Finland – On 2 June 2023 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL362,6953.83CEUX1,1353.84AQEU1,6303.81TQEX1,9403.81Total367,4003.83 * Rounded to two decimals On 3 February 2022, Nokia announced that its Board of Directors is initiating a share buyback program under the authorization granted by Nokia’s Annual General Meeting on 8 April 2021 to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The second phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 5 April 2022 started on 2 January 2023 and end
BlueCat acquires network infrastructure monitoring and automation platform Indeni2.6.2023 19:00:00 CEST | Press release
Customers will gain an enhanced ability to maintain network resiliency TORONTO, June 02, 2023 (GLOBE NEWSWIRE) -- BlueCat Networks, a leading provider of mission-critical network and cloud infrastructure software for reliable and secure DNS, DHCP, and IP address management (collectively known as DDI), announced today that it has acquired Indeni. Moelis & Company acted as financial advisors to BlueCat. Financial terms were not disclosed, and the deal is subject to regulatory approval. Indeni’s platform helps network operations (NetOps) teams assure the health of their network appliances such as firewalls, load balancers, and secure web proxies. It analyzes device configurations, metrics, and logs through deep domain expertise, codified as knowledge. And it alerts administrators about existing and potential issues, using a global, crowd-sourced knowledge base to identify and recommend remediation steps using automation. Customers using Check Point, Palo Alto Networks, Fortinet, F5, and m